IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects
Yan, Yucheng1; Qian, Jiaqi1; Chen, Nan2; Huang, Zhaoxing3; Jiang, Gengru4; Li, Xuewang5; Lin, Hongli6; Liu, Liqiu7; Wang, Mei8; Xing, Changying9,10; Yu, Xueqing11; Zuo, Li12; Amdahl, Michael13; Khan, Samina13
关键词Paricalcitol Secondary Hyperparathyroidism End-stage Renal Disease Hemodialysis
刊名CLINICAL NEPHROLOGY
2014
DOI10.5414/CN107762
81期:1页:20-29
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Urology & Nephrology
研究领域[WOS]Urology & Nephrology
关键词[WOS]CHRONIC KIDNEY-DISEASE ; VITAMIN-D ; ALKALINE-PHOSPHATASE ; SERUM-CALCIUM ; BONE-DISEASE ; HEMODIALYSIS ; CALCITRIOL ; MORTALITY ; SURVIVAL ; CKD
英文摘要

Aim: Prevalence of secondary hyperparathyroidism (SHPT), a renal disease complication, is increasing in China. Available therapies may not optimally control SHPT, particularly in patients with hypercalcemia, hyperphosphatemia, and parathyroid hyperplasia. This study examined efficacy and safety of two dosing regimens of selective vitamin D receptor activator paricalcitol. Materials and methods: Subjects with SHPT (n = 216) undergoing hemodialysis were treated with paricalcitol IV for 12 weeks. One group was treated according to the EU paricalcitol package insert (PI) (initial mu g dose based on iPTH/80), and the other was treated according to the US PI (initial dose of 0.04 mu g/kg). Dose titration was based on iPTH and serum calcium (Ca) and phosphorus (P) levels. Results: The primary endpoint of two consecutive >= 30% iPTH decreases was achieved by 88.6% and 55.9% of subjects in the EU and US PI groups, respectively. Noninferiority of the EU PI group vs. the US PI group was demonstrated (lower bound of the 1-sided 97.5% CI = 21.3%). Superiority of the EU PI group was shown (lower limit > 0%) and confirmed by Fisher′s exact-test (p < 0.001); both groups showed similar achievement of recommended KDIGO iPTH levels. Ca and P levels were relatively constant. Conclusion: Both EU and US PI paricalcitol dosing strategies effectively reduced iPTH levels in Chinese subjects with SHPT, with minimal impact on Ca and P levels.

语种英语
WOS记录号WOS:000335444800003
资助机构AbbVie Inc. ; AbbVie
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55820
专题北京大学第二临床医学院
作者单位1.AbbVie Inc, N Chicago, IL USA
2.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
3.Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China
4.Peking Univ, Hosp 1, Beijing 100871, Peoples R China
5.Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
6.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai 200001, Peoples R China
7.Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200001, Peoples R China
8.Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China
9.Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200001, Peoples R China
10.Beijing Union Med Coll Hosp, Beijing, Peoples R China
11.Qingdao Univ, Coll Med, Affiliated Hosp, Qingdao 266071, Peoples R China
12.Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
13.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Yan, Yucheng,Qian, Jiaqi,Chen, Nan,et al. Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects[J]. CLINICAL NEPHROLOGY,2014,81(1):20-29.
APA Yan, Yucheng.,Qian, Jiaqi.,Chen, Nan.,Huang, Zhaoxing.,Jiang, Gengru.,...&Khan, Samina.(2014).Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.CLINICAL NEPHROLOGY,81(1),20-29.
MLA Yan, Yucheng,et al."Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects".CLINICAL NEPHROLOGY 81.1(2014):20-29.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yan, Yucheng]的文章
[Qian, Jiaqi]的文章
[Chen, Nan]的文章
百度学术
百度学术中相似的文章
[Yan, Yucheng]的文章
[Qian, Jiaqi]的文章
[Chen, Nan]的文章
必应学术
必应学术中相似的文章
[Yan, Yucheng]的文章
[Qian, Jiaqi]的文章
[Chen, Nan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。